The RADV Audit Landscape

Between 2024 and 2025, the HHS Office of Inspector General (OIG) published Risk Adjustment Data Validation (RADV) audit findings for 10 Medicare Advantage organizations. These audits examined whether MA plans submitted accurate diagnosis codes to CMS — the codes that determine how much the federal government pays each plan per enrollee.

The findings were consistent across every plan: 70–99% of sampled high-risk diagnosis codes were unsupported or miscoded, resulting in millions of dollars in estimated overpayments per organization.

With Medicare Advantage now covering approximately 45% of all Medicare payments, accurate risk adjustment is a major federal financial priority. These audits are not one-off events — they are part of a systematic OIG enforcement series targeting the same high-risk diagnosis categories across plans nationwide.

OIG vs. CMS RADV Audits: All 10 audits in this analysis are OIG audits — conducted by an independent federal watchdog. OIG selects plans based on risk criteria, targets specific high-risk diagnosis categories, and publishes findings publicly. CMS also conducts routine RADV audits separately. Both audit against the same standard: whether submitted diagnosis codes are supported by medical records.

Every audited plan followed the same structure: stratified random sampling by diagnosis group, independent medical review, and findings broken down by high-risk diagnosis category. All 10 plans received the same three recommendations: refund overpayments, self-identify similar errors, and improve compliance procedures. All 10 disagreed.

Key Findings at a Glance

Across the 10 audited plans, four metrics define the scale of the problem:

10
Plans Audited
2024–2025 OIG findings
93%
Cancer Dx Error Rate
Avg across all cancer categories
$59M
Largest Penalty
Extrapolated to full population
11x
Extrapolation Factor
Sample error → full-plan penalty

Near-Universal Miscoding: Acute Stroke (99%), Colon Cancer (98%), Acute MI (96%) — error rates so high they signal systemic coding failures across the industry, not isolated chart-level mistakes.

Highest Dollar Exposure Per Enrollee: Lung Cancer ($5,937/yr) and Ovarian Cancer ($5,242/yr) carry 3–6x the financial risk of other categories. Together, cancer diagnoses account for 62% of all audit overpayments.

All 12 Diagnosis Categories Under OIG Scrutiny

OIG targeted the same high-risk diagnosis groups across plans. The consolidated table below ranks all 12 audited categories by average overpayment per enrollee-year — the most direct measure of financial exposure per finding.

Diagnosis Plans Sample Errors Error Rate Overpayment $/Yr
Lung Cancer Cancer 8 251 229
91%
$1,491,091 $5,941
Ovarian Cancer Cancer 2 60 58
97%
$314,520 $5,242
Pressure Ulcer Non-Cancer 3 83 29
35%
$215,925 $2,601
Embolism Non-Cancer 8 240 199
83%
$528,087 $2,200
Colon Cancer Cancer 8 240 234
98%
$523,501 $2,181
Acute Stroke Non-Cancer 8 240 238
99%
$435,421 $1,814
Acute MI Non-Cancer 8 240 231
96%
$386,008 $1,608
Sepsis Non-Cancer 5 170 69
41%
$190,219 $1,119
Breast Cancer Cancer 8 240 229
95%
$287,528 $1,198
Prostate Cancer Cancer 8 240 211
88%
$250,049 $1,042
Vascular Claudication Non-Cancer 1 30 3
10%
$3,739 $125
Major Depressive Disorder Non-Cancer 1 30 1
3%
$1,998 $67

Error Rate by Diagnosis Category

Visualizing error rates highlights the distinction between near-universal miscoding (cancers and acute conditions) and selectively flagged categories (Sepsis, Pressure Ulcer):

Acute Stroke
99%
Colon Cancer
98%
Ovarian Cancer
97%
Acute MI
96%
Lung Cancer
91%
Breast Cancer
95%
Prostate Cancer
88%
Embolism
83%
Sepsis
41%
Pressure Ulcer
35%

Cancer   Non-Cancer  ·  Vascular Claudication (10%) and Major Depressive Disorder (3%) omitted

Plan-Level Audit Exposure

While error patterns are consistent across plans, the financial exposure varies significantly based on plan size and enrollee universe. Below are the 10 audited organizations and their estimated overpayments:

Organization Sample Non-Compliant Estimated Overpayment
MMM Healthcare 44% (87/200) $59M
Humana Health Plan 84% (202/240) $13.1M
Independent Health 93% (230/247) $7.0M
Coventry Health 83% (249/300) $6.9M
BCBS Michigan 91% (192/210) $6.4M
EmblemHealth 67% (134/200) $130.7M*
UCare Minnesota 86% (254/294) $4.7M
Health Assurance 83% (222/269) $4.3M
MediGold 90% (189/210) $3.7M
Triple-S Advantage 73% (204/281) $297K*

* Triple-S Advantage amount is not extrapolated in the published report. * EmblemHealth uses HCC-level audit methodology (differs from diagnosis-group approach used by other plans); figure not directly comparable.

Audit Timeline Lag: These audits cover payment years 2016–2019, yet were published in 2024–2025 — reflecting the long lag in federal audit cycles. The 2023 CMS Final Rule on RADV extrapolation limits recovery to 2018 forward, but plans should expect current-year data to be audited within a similar 5–7 year window.

Cancer vs. Non-Cancer: Where the Money Is

Cancer diagnoses dominate the financial exposure in RADV audits. Understanding this split is critical for prioritizing remediation efforts.

Cancer Diagnoses

Share of Total Overpayments 62%
Average Error Rate 93%
Avg $/Enrollee-Year $2,780
Total Sample Overpayment $2,866,689
Categories at Universal Audit 5 of 5

Non-Cancer Diagnoses

Share of Total Overpayments 38%
Average Error Rate 75%
Avg $/Enrollee-Year $1,705
Total Sample Overpayment $1,761,397
Categories at Universal Audit 3 of 7

Cancer Category Breakdown

Cancer Type Plans Sample Errors Error Rate Overpayment Avg $/Yr
Lung Cancer 8 251 229 91% $1,491,091 $5,941
Ovarian Cancer 2 60 58 97% $314,520 $5,242
Colon Cancer 8 240 234 98% $523,501 $2,181
Breast Cancer 8 240 229 95% $287,528 $1,198
Prostate Cancer 8 240 211 88% $250,049 $1,042
All Cancers 1,031 961 93% $2,866,689 $2,780

The Single Biggest Lever: Lung Cancer alone drives 52% of cancer overpayments ($1.49M of $2.87M) despite having a similar sample size to other categories. It is both the highest-cost and most consistently audited category — present in every future RADV audit with near-certainty.

Non-Cancer Category Breakdown

Diagnosis Plans Sample Errors Error Rate Overpayment Avg $/Yr
Pressure Ulcer 3 83 29 35% $215,925 $2,601
Embolism 8 240 199 83% $528,087 $2,200
Acute Stroke 8 240 238 99% $435,421 $1,814
Acute MI 8 240 231 96% $386,008 $1,608
Sepsis 5 170 69 41% $190,219 $1,119
Vascular Claudication 1 30 3 10% $3,739 $125
Major Depressive Disorder 1 30 1 3% $1,998 $67
All Non-Cancers 1,033 770 75% $1,761,397 $1,705

Cardiovascular Is the Second Priority: Embolism and Acute Stroke together contribute $964K in sample overpayments — more than Breast and Prostate Cancer combined — making cardiovascular diagnoses the clear second priority for payor remediation after cancer.

Error Rate vs. Dollar Risk: They Don't Always Align

A high error rate does not automatically mean high financial risk — and vice versa. Understanding this distinction is essential for prioritizing remediation efforts:

High Error Rate + High $/Enrollee
Lung Cancer, Ovarian Cancer

Maximum financial risk. Top priority for immediate remediation. Every unsupported code is expensive and nearly every code is unsupported.

Low Error Rate + High $/Enrollee
Pressure Ulcer

Documentation is harder but defensible when done right. Only 35% error rate but $2,601/enrollee. Worth targeted investment in documentation quality.

High Error Rate + Low $/Enrollee
Acute Stroke, Colon Cancer

Volume problem. 98–99% error rates suggest systemic miscoding — not isolated cases. Operationally the easiest fix through process correction.

Low Error Rate + Low $/Enrollee
Sepsis, Vascular Claudication

Lower immediate priority, but Sepsis is expanding into standard audit batteries. Build protocols now before it becomes a universal target.

The 11x Extrapolation Multiplier

The most important financial dynamic in RADV audits is not the sample error — it's the extrapolation. OIG doesn't just recover overpayments found in the sample. It extrapolates findings to the entire enrollee universe.

11x
Average Extrapolation Multiplier
Sample overpayments averaged ~$536K per plan. Extrapolated penalties averaged ~$6.1M per plan. Every $1 of error found in audit translates to ~$11 in penalties.

This means pre-submission validation doesn't just prevent the face-value error — it prevents the amplified penalty. A single Lung Cancer code corrected before submission doesn't save $5,937. With the 11x multiplier, it saves approximately $65,000 in extrapolated penalty exposure.

The Only Free Intervention Point: Once a diagnosis code is submitted to CMS and flagged in an OIG audit, a plan's options are limited: repay or dispute — both costly. Pre-submission validation is the only moment where correction is cost-free. Clean data goes to CMS. Flagged data goes back for resolution. No audit. No penalty. No dispute.

How RADV Scrubber Works

RADV Scrubber is a rules engine that processes member data through automated clinical, demographic, and service validation — surfacing discrepancies before CMS submission. It is part of the Precise Health Risk Compass platform.

1

Access Member Data

Prior-year claims (IP/OP/Rx), MA04 & MOR — or live encounter data (837P/837I)

2

Extract & Scrub

Each member flows through the RADV Scrubber REST API for fast, automated rules-based validation

3

Analyze & Detect

Rules engine validates clinical, demographic, and service data across 60+ high-risk condition groups

4

Flag & Prioritize

Discrepancies surfaced with finding comments; targeted chase lists ranked by RAF score impact

5

Resolve & Submit

Coders and auditors resolve flags; clean, validated data submitted to CMS EDPS/RAPS

Dual Workflow Integration

RADV Scrubber supports both workflow models — catching errors at the point of encounter submission and during retrospective review:

Concurrent Workflow

Flags encounter data before Claims Processing & CMS EDPS/RAPS submission.

Input 837P / 837I Encounter Data
Output Clean submission to CMS
Flagged Retro Audit queue

Retrospective Workflow

Reviews prior-year data and outputs Supplemental Data or Chart Review Records.

Input Prior-Year Claims + Member/Provider
Output Supp. Data / Chart Review Records
Flagged Supplemental data to CMS

60+ High-Risk Condition Groups  •  7,000+ HCC-Associated ICDs  •  20+ Validation Types  •  REST API  •  HIPAA Compliant  •  ISO 27001:2022

What RADV Scrubber Validates

Three validation dimensions — clinical accuracy, demographic consistency, and service pattern verification — across all OIG/CMS-audited HCC categories and beyond.

Clinical Data

Dx code rules, acute vs. history status, cancer/mental health/end-stage classification; labs, radiology, medications & therapeutic validation; anatomical conflicts & ICD-10 guideline checks

Demographic Data

Missing/mismatched member & provider specialties; gender conflicts, age-based condition checks; date-of-service overlaps and enrollment validation

Service Data

Place of service, visit frequency, provider specialty checks; mutually exclusive & conflicting diagnosis code detection

Audit Finding → RADV Scrubber Capability

Every OIG audit finding maps directly to a RADV Scrubber capability. The same errors flagged after the fact by OIG are caught before submission:

Audit Finding 95–99% error rates in Lung, Colon, Ovarian Cancer codes
RADV Scrubber Flags invalid/unsupported ICDs across 7,000+ HCC-associated codes
Audit Finding Near-universal Acute Stroke & Acute MI miscoding
RADV Scrubber 20+ validations on high-risk codes catch systematic coding errors
Audit Finding Embolism codes submitted without clinical support
RADV Scrubber Clinical data validation checks for missing or mismatched provider/service data
Audit Finding Pressure Ulcer & Sepsis emerging as new OIG audit targets
RADV Scrubber Covers 60+ high-risk condition groups — well beyond current OIG scope
Audit Finding Plans didn't know which members were at risk
RADV Scrubber Builds targeted chase lists with flagged members, ICDs, and RAF scores
Audit Finding Errors found only at audit time (retrospective)
RADV Scrubber Works with both concurrent and retrospective audit workflows
Audit Finding Missing or unlocatable medical records at audit
RADV Scrubber Routes flagged issues for retrospective chart reviews before submission
Audit Finding Mutually exclusive or conflicting diagnosis codes
RADV Scrubber Explicitly detects mutually exclusive codes and conflicting demographics

ICD-10 Guideline Auditor

Complementing RADV Scrubber, the ICD-10 Guideline Auditor provides automated ICD-10 coding guideline validation — embedded directly in your HCC coding workflow, surfacing errors before submission.

100% ICD-10 VALIDATION IN SECONDS

Automates 100% of ICD-10 coding guideline validation during HCC coding. Every code validated instantly — before claim submission.

  • Code First, Use Additional Code, Excludes1 & Specificity checks
  • Laterality, Severity, and Combination Code validation
  • Gender, End-Stage, Historical vs. Active conflict detection
  • Intelligent code suggestions — surfaces new revenue opportunities
  • Up to 50% improvement in auditor efficiency via REST API

What RADV Scrubber Can Save Your Plan

The only cost-free intervention is catching errors before CMS submission. Every avoided error prevents approximately 11x its value in extrapolated penalties.

Small Plan
$3.7M
Audit Exposure
50% Errors Prevented $1.85M
75% Errors Prevented $2.78M
90% Errors Prevented $3.33M
MediGold / Triple-S audit baseline
Typical Plan
$6.2M
Audit Exposure
50% Errors Prevented $3.1M
75% Errors Prevented $4.65M
90% Errors Prevented $5.58M
Average of 8 audited plans
Large Plan
$13.2M
Audit Exposure
50% Errors Prevented $6.6M
75% Errors Prevented $9.9M
90% Errors Prevented $11.9M
Humana audit data baseline

Savings by Diagnosis Priority

If a plan focuses RADV Scrubber specifically on the highest-exposure categories:

Focus Area Total Overpayment (10 Plans) Savings at 75%
All categories $4,628,086 $3.5M
Cancers only $2,866,689 $2.1M
Non-cancers only $1,761,397 $1.3M
Lung Cancer alone $1,491,091 $1.1M

Sample overpayments above are from 210–300 enrollee-year samples. Extrapolated to full plan populations, these figures scale 10–15x.

Beyond Direct Penalties: Plans also save on audit response costs (legal, medical record retrieval, contractor fees) and reputational risk from public OIG findings — costs that don't show up in the overpayment figures but are material in practice.

Strategic Recommendations for Payors

Based on the OIG findings across all 10 audited plans, here are prioritized actions for Medicare Advantage organizations:

Immediate: Audit Your Highest-Exposure Categories

Audit your own Lung Cancer, Ovarian Cancer, and Embolism records before OIG does. These carry $2,196–$5,937 per enrollee-year and have 83–97% error rates. Every unsupported code is a significant financial liability.

Systematic: Fix Process-Level Coding Failures

Acute Stroke (99%) and Colon Cancer (98%) error rates indicate process failures, not individual chart problems. Implement automated pre-submission validation to catch these systematic miscoding patterns at scale.

Proactive: Prepare for Expanding Audit Scope

Sepsis and Pressure Ulcer appeared in only 3–5 plans today but are being phased into standard audit batteries. Build documentation protocols now — before they become universal targets in all plans.

Ongoing: Ensure Record Retrievability

Several plans lost audit cases purely due to missing medical records — not wrong codes. Ensure records are retrievable, complete, and linked to submitted diagnosis codes.

The Core Six Are Unavoidable: Acute Stroke, Acute MI, Lung/Breast/Colon/Prostate Cancer, and Embolism appeared in 8 of 10 plans with 30 samples each — these are OIG's standard battery. Every MA plan should assume these categories will be audited. There is no avoiding them.

Lung Cancer: Plan-by-Plan Audit Data

As the single highest-cost diagnosis category, Lung Cancer warrants a detailed plan-by-plan breakdown. The consistency of findings across 8 plans underscores the systemic nature of the problem.

Plan Sample Errors Error Rate Overpayment $/Enrollee
UCare Minnesota 30 29 97% $238,858 $7,962
BCBS Michigan 30 29 97% $209,565 $6,986
Independent Health 30 30 100% $207,261 $6,909
Health Assurance 30 26 87% $197,559 $6,585
Coventry Health 30 24 80% $181,489 $6,050
Humana 30 26 87% $169,675 $5,656
MediGold 30 28 93% $169,417 $5,647
Triple-S Advantage 41 37 90% $117,267 $2,860
Total / Average 251 229 91% $1,491,091 $5,941

References

Source Data: All audit findings, error rates, and overpayment figures cited in this analysis are drawn from publicly available OIG RADV audit reports for Medicare Part C. The full collection of OIG reports — including the 10 audits referenced here — can be accessed at:
HHS OIG Reports — Medicare Part C (Medicare Advantage)

Don't Wait for OIG to Find Your Errors

RADV Scrubber validates diagnosis codes across 60+ high-risk condition groups before CMS submission — eliminating audit exposure at the only point where correction is cost-free.

Schedule a Demo